
---
title: '针对狂犬病的免疫力（免疫抑制患者的免疫反应）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829587'
author: 科学网
comments: false
date: Fri, 31 Dec 2021 13:51:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829587'
---

<div>   
<h1 style="margin-top:19px;margin-right:0;margin-bottom:19px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 32px">针对狂犬病的免疫力（</span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 32px">6-a</span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 32px">）（免疫抑制患者</span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 32px">的免疫反应</span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 32px">）</span></strong></h1><h1 style="margin-top:19px;margin-right:0;margin-bottom:19px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #2F496F;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">      </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 24px">说明：</span></strong></h1><h1 style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 14px">  </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">2011年2月，WHO正式发布了《</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #C00000;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px"><span style="font-family:KaiTi">疫苗接种的免疫学基础系列，第</span>17分册：狂犬病(The Immunological Basis</span></strong><strong>　</strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #C00000;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">for Immunization Series，Module 17: Rabies)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">》。此文献深入浅出地讲解了与狂犬病相关的免疫学基本知识，回答了人们普遍关心的许多理论问题和实践问题。本博客当年曾全文翻译了此文献。</span></strong></h1><h1 style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">  </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">WHO于2017年对此文献进行了修订，更新了大量内容，可增进我们对狂犬病相关免疫学知识的系统认识和深入理解。本博客近期将陆续选择该更新版的较重要的内容进行介绍。</span></strong></h1><h1 style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">  </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px"><span style="font-family:KaiTi">本次介绍该文献的第</span>2章：</span></strong></h1><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><span style="font-family: StempelGaramond-Roman;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 29px">2.  针对狂犬病的免疫力（Immunity）</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><span style="font-family: StempelGaramond-Roman;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 24px">本章目录</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 20px">2.1  预防临床疾病</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 20px">2.2  狂犬病疫苗</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 20px">2.3  疫苗接种的免疫反应（体液免疫和细胞免疫）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 20px">2.4  被动免疫的作用</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 20px">2.5 主动免疫接种的途径</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 20px">2.6 不同危险群体的免疫反应</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: StempelGaramond-Bold;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 29px"> 2.6  不同危险群体的免疫反应（Immune response in different risk groups）</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">现代</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">CCV（细胞培养狂犬病疫苗</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">）是世界上最具免疫原性的疫苗之一，根据</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">WHO（世界卫生组织</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">）的建议，立即接受</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">PEP（暴露后预防</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">）的患者中极少报告人狂犬病死亡</span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">。有若干报道检测了不同人群接种狂犬病疫苗后免疫反应是或可能是有受到抑制的。伊朗最近的一项研究对</span>50名因II类和III类咬伤而进行PEP的人作了VNA（病毒中和抗体）评估，这些人原本患有不同疾病。这些病人包括以下患病状况:怀孕;1型糖尿病;2型糖尿病;慢性乙型肝炎病毒感染;不同类型的癌症;由于接受皮质类固醇治疗类风湿关节炎和红斑狼疮而导致免疫功能低下。结果</span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">癌症和</span>II型糖尿病患者的滴度较低，但</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #0070C0;font-size: 19px"><span style="font-family:Microsoft YaHei UI">所有患者在第</span>14天都出现了高于0.5 IU/mL</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">（国际单位</span>/毫升）</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #0070C0;font-size: 19px">的免疫反应</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">。</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';font-weight: bold;font-size: 29px">I) </span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 29px"> </span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 24px">免疫抑制患者</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 24px">（</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 24px"> Immunosuppressed patients</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 24px">）</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:Microsoft YaHei UI">狂犬病疫苗在几乎所有人群中都具有高度的免疫原性，可能只有</span>CD4+细胞非常低的免疫抑制患者例外。</span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">一些已发表的研究已经检验了狂犬病疫苗在</span><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">HIV（艾滋病毒</span></span><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">）感染患者中的免疫应答。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">最近的一项研究报告了接受间歇性持续</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">抗逆转录病毒治疗</span>(ART)</span></span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">的患者</span>VNA滴度较低。该研究的目的是研究不坚持抗逆转录病毒疗法对HIV感染患者新抗原免疫应答的影响。在该项研究中，一组CD4+细胞数为200－350个细胞/微升的患者接受了6个月的抗病毒抑制治疗。一组研究对象随后被分成两组，并接受三针PrEP狂犬病疫苗接种方案。第1组(25例)持续不间断ART治疗72周，第2组(26例)间歇ART治疗72周。两组患者的VNA反应最初相似。然而，在第2组中，VNA滴度下降的速度更快，在第80周，第1组中74%的受试者VNA滴度高于0.5 IU/mL，而第2组中只有24%的受试者VNA滴度高于0.5 IU/mL。两组患者在研究结束时，无论抗体水平如何，均接受一针狂犬病疫苗加强针。在加强针后，每组中VNA滴度高于0.5 IU/mL的受试者所占的比例相似：在第1组测试的受试者中占100%，在第2组测试的受试者中占95%，这表明</span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">ART间歇治疗并不明显损害引发回忆反应的能力</span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">另一项研究调查选定的感染</span>HIV的成年人群对CCV 的免疫反应，在第0、3、7、14和30天共接受5针PEP肌内注射后，</span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">CD4 +计数低于400的HIV感染的有症状患者中只有57%的人发展了高于0.5 IU/ml的可检测到的VNA响应</span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">在一项研究中，</span>10名CD4+计数在25至472之间的HIV感染成人给予ID（皮内）途径多位点PEP接种，即在第0、3和7天各给予4针CCV，在第28天和90天给予2针CCV(4-4-4-0-2-2)。所有10例患者的免疫反应均低于预期;其中2例患者在第14天VNA滴度没有超过0.5 IU/ml，其中1例患者在第30天VNA滴度仍没有超过0.5 IU/ml。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">在另一项研究中，对</span>13名CD4+计数低于正常水平的HIV感染儿童进行了三针IM PrEP方案的免疫应答检查，并将其与9名未感染HIV儿童的免疫应答进行了比较。在这项研究中，</span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">CD4+细胞读数低于15%正常值的儿童与对照组相比，VNA滴度显著降低，而这13名HIV感染儿童中有4名甚至没有出现任何可测量的VNA</span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">在最近的一项研究中，对接受</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">高效抗逆转录病毒治疗</span>( highly-active antiretroviral therapy ，HAART</span></span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">)的HIV感染患者接种CCV后的免疫反应进行了检测，结果发现在老年HIV感染患者中IgG和IgM滴度略低。然而，这项研究也报告了</span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">63%接受HAART治疗的患者在初次疫苗接种5年后仍有可测量到的抗体滴度</span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">另一项研究评估对免疫抑制患者更有效的的疫苗接种方案。两组</span>HIV阳性个体：一组CD4 +计数低于200，另一组CD4 +计数超过200，都按修改的8位点系列皮内PEP方案接种疫苗：在第0、3、7、14和30天的每一天进行8个位点的皮内注射。结果</span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:Microsoft YaHei UI">所有受试者的抗体滴度均高于</span>0.5 IU/mL。</span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">在</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">实体器官移植</span>(</span></span></strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">solid organ transplantion，</span></span><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">SOT)</span></span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">后接受免疫抑制治疗期间暴露于狂犬病的儿童使用</span>PEP也被报道在所有患者中都是成功的。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">有一些病人在不知情的情况下接受了受感染病人捐赠的器官，发生了狂犬病。在所有报告的病例中，原始器官供者的狂犬病诊断直到受者被诊断为狂犬病数周或数月后才被确认。在接受</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">实体器官移植</span>(SOT)</span></span></strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">之前、期间或之后接受免疫抑制药物的患者中，很少有关于</span>PEP免疫反应的数据。</span><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px"><span style="font-family:Microsoft YaHei UI">最近的一篇综述文章研究了接受狂犬病毒感染器官的</span>SOT受体的免疫反应。在该报告审查的两项研究中，VNA水平在达到适当水平28天后出现下降。VNA滴度下降比在健康患者中更快。在另一篇研究接受了狂犬病毒感染器官移植的免疫抑制受体的VNA滴度的论文中，</span><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">5针PEP方案后的VNA达到可检测到的水平，但明显低于健康人报告的水平</span></span><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;font-size: 19px">。</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:56px;line-height:200%;background:rgb(255,255,255)"><span style="font-family: StempelGaramond-Roman;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">（</span><strong><span style="font-family: StempelGaramond-Roman;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 21px">未完待续）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:46px;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 24px">参考文献：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;line-height:200%;background:rgb(255,255,255)"><span style="font-family: Helvetica;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">World Health Organization. (‎2017)‎. </span><strong><span style="font-family: Helvetica;color: #C00000;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">The immunological basis for immunization series: module 17: rabies</span></strong><strong><span style="font-family: Helvetica;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">. </span></strong><em><span style="font-family: Helvetica;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">World Health</span></em><em><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> </span></em><em><span style="font-family: Helvetica;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">Organization</span></em><span style="font-family: Helvetica;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">. </span><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">   </span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;line-height:200%;background:rgb(255,255,255)"><a href="https://apps.who.int/iris/handle/10665/259511" target="_blank"><span style="font-family: Helvetica;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">https://apps.who.int/iris/handle/10665/259511</span></a><span style="font-family: Helvetica;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">. License: CC BY-NC-SA 3.0 IGO</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 24px">相关博文：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1316244" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829587" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 接种狂犬病疫苗后，抗体能维持多久?(1) （WHO专题文献选译）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-12</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:32px;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1316511" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"><span style="font-family:Tahoma">接种狂犬病疫苗后，抗体能维持多久</span>?(2)（WHO专题文献选译）</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-14</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1317338" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829588" title alt="image.png" referrerpolicy="no-referrer"></a><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">  接种狂犬病疫苗后，抗体能维持多久?(3) （WHO专题文献选译）</span></span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-16</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1317055" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829592" title alt="image.png" referrerpolicy="no-referrer"></a><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">  接种狂犬病疫苗后，抗体能维持多久?(4) （WHO专题文献选译）</span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-18</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1317338" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829589" title alt="image.png" referrerpolicy="no-referrer"></a> <span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 针对狂犬病的免疫力（1）（WHO专题文献选译）</span></span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px">   2021-12-20</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;line-height:200%;background:rgb(255,255,255)"><span style="font-family: StempelGaramond-Roman;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> </span><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829591" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> </span><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1317603" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"><span style="font-family:Tahoma">针对狂犬病的免疫力（</span>2）（WHO专题文献选译）</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-22</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:48px;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1317983" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"><span style="font-family:Tahoma">针对狂犬病的免疫力（</span>3）（WHO专题文献选译）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-24</span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> </span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:48px;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1318146" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"><span style="font-family:Tahoma">针对狂犬病的免疫力（</span>3-b）（WHO专题文献选译）</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-26</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:48px;line-height:200%;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1318434" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"><span style="font-family:Tahoma">针对狂犬病的免疫力（</span>4）（被动免疫的作用）</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px"> 2021-12-28</span></p><p style="line-height: 200%;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=829590" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;line-height: 200%;color: #333333;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 14px;background: #FFFFFF"> </span><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1318595" target="_blank"><strong><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px;background: #FFFFFF">  </span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px;background: #FFFFFF"><span style="font-family:Tahoma">针对狂犬病的免疫力（</span>5）（主动免疫接种的途径）</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-variant-numeric: normal;font-variant-east-asian: normal;font-size: 16px;background: #FFFFFF"> 2021-12-29</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-347754-1318974.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-347754-1318974.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1318595.html" target="_black">针对狂犬病的免疫力（5）（主动免疫接种的途径）</a><br>                    <!--大赛结束-->
                                        
  
</div>
            